elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q40333043-3735A93B-37A6-4501-AAEF-BBBDE78ED765
Q40333043-3735A93B-37A6-4501-AAEF-BBBDE78ED765
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40333043-3735A93B-37A6-4501-AAEF-BBBDE78ED765
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
P2860
Q40333043-3735A93B-37A6-4501-AAEF-BBBDE78ED765
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40333043-3735A93B-37A6-4501-AAEF-BBBDE78ED765
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f8bc1af5bf01a21d64c43015022561e5e1f22aa4
P2860
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.